Cidara Therapeutics Inc., of San Diego, said the FDA granted orphan drug designation to its drug candidate, CD101 IV, for the treatment of candidemia and invasive candidiasis. Phase I data demonstrated the safety and tolerability of up to three doses of high exposure, once-weekly CD101 IV. A phase II experiment will be initiated in the first half of 2016.